Nav: Home

Results with new bioresorbable stent (BRS) technologies reported at EuroPCR 2017

May 19, 2017

Paris, France: Promising results were reported in late-breaking trials with novel bioresorbable stent technologies at EuroPCR 2017, paving the way for ongoing developments in stents that are dissolved or reabsorbed after achieving vessel expansion in percutaneous coronary intervention procedures.

Researchers reported results with seven bioresorbable stent technologies:
  • Nine-month clinical and imaging outcomes of a novel ultra-high molecular weight poly-L-lactide BRS. A prospective multicenter international investigation: The RENASCENT II study.

Results from the prospective multicentre RENASCENT II study of the Amaranth Medical APTITUDE BRS stent, a novel ultra-high molecular weight poly-L-lactide BRS with a new, thinner strut (120 μm), reported no events at one year in 60 patients treated for single lesion coronary artery stenosis. Coronary artery imaging with optical coherence tomography (OCT) demonstrated excellent wall apposition and full, homogenous endothelial wall coverage, with no valleys and peaks between regions with struts and those without struts. "The results are very positive. The scaffold delivers a very low medium-term event rate and the stent favours good laminar flow in blood vessels," said lead author Antonio Colombo, from San Raffaele Scientific Institute, Milan, Italy, although he cautioned that the study was small.
  • Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and four-year clinical and imaging results

The key imaging results from the DESolve Nx Study, a prospective registry including 126 patients, showed a mean lumen gain of 9% at six months, as measured by intravascular ultrasound (IVUS), and an angiographic late luminal loss (LLL) of 0.2mm. "This is a clinical breakthrough as no other BRS technology has been successful in achieving such impressive results and, at the same time, degrading in six months with near complete resorption (mass loss) in one year," said lead author Stefan Verheye, from ZNA Middelheim, Antwerpen, Belgium. He added that the 18-month and 36-month imaging data showed sustained efficacy and confirmed the degradation and complete resorption (mass loss) in one year. There were no late or very late definite or probable scaffold thromboses and no target lesion revascularisations from years two to four. Verheye concluded, "Early degradation and early resorption is not only an intuitive wish, it is a must for a BRS technology in order to succeed. Companies attempted but failed to achieve clinical effectiveness, primarily due to chronic recoil of their scaffolds. In an effort to resolve this issue, companies had to revert to much longer degradation and resorption profiles. The Elixir DESolve scaffold is the only technology to date to resolve the chronic recoil issue, as evidenced by the Nx trial data."
  • One-year clinical and multislice computer tomography results with a thin-strut poly-L-lactic acid-based sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease: MeRes-1 study

One-year results from the first-in-man MeRes-1 study of the safety and efficacy of the novel MeRes 100 scaffold in 108 patients with 116 de novo coronary artery lesions showed that the composite endpoint of cardiac death, myocardial infarction (MI) and ischaemia-driven target lesion revascularisation (ID-TLR) occurred in one patient (0.93%). There was no scaffold thrombosis. One-year computed tomography (CT) angiography demonstrated that all scaffolds were patent. Six-month quantitative coronary angiography showed a low rate of late lumen loss and no restenosis. Intravascular ultrasound and OCT analyses also gave favourable results, reported Ashok Seth, from Fortis Escort Heart Institute, New Delhi, India. He said, "The positive results of this study provide the basis for a larger, randomised trial against a second-generation metallic drug-eluting stent."

Data were also reported for the following studies, but results were not available to include in the press release:
  • The FANTOM II study: first report for the 12-month clinical outcomes of the Fantom sirolimus-eluting bioresorbable scaffold - Alexandre Abizaid, Instituto Dante Pazzanese, Sao Paulo, Brazil

  • Multicentre evaluation of a novel 120μm novolimus-eluting, fully coronary BRS: first report of six-month clinical and imaging endpoints - Alexandre Abizaid, Instituto Dante Pazzanese, Sao Paulo, Brazil

  • Short and midterm safety, clinical performance and multi-modality imaging results of the drug-eluting absorbable metal scaffold: combined data of the BIOSOLVE-II and BIOSOLVE-III trials - Michael Haude, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany

  • A first-in-man study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in patients with coronary artery disease (FUTURE-I): one-year clinical and imaging outcomes - Bo Xu, Fu Wai Hospital, Beijing, China
Contact information

Antonio Colombo
San Raffaele Scientific Institute
Milan, Italy

Stefan Verheye
ZNA Middelheim
Antwerpen, Belgium

Ashok Seth
Fortis Escorts Heart Institute
New Delhi, India

Michael Haude
Städtische Kliniken Neuss
Lukaskrankenhaus GmbH
Neuss, Germany

Alexandre Abizaid
Instituto Dante Pazzanese
Sao Paulo, Brazil

Xu Bo
Fu Wai Hospital
Beijing, China

Corresponding session

EuroPCR 2017 session: Tuesday 16 May 12.00-13.30, Hot Line/Late-breaking Trials, Coronary Interventions, Stents and Scaffolds; Room 351

Help for journalists to cover EuroPCR 2017
For any press-related inquiries, please contact:

EuroPCR Press Coordinator, Isabelle Uzielli

Register and attend EuroPCR 2017 as a journalist
Press registration for EuroPCR is open to accredited journalists, free of charge.
Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to

EuroPCR press releases
EuroPCR press releases can be found at

Attend press briefings
For the press briefing schedule check

EuroPCR abstracts
Abstracts are available online at

Notes to Editors
What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 11,500 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Milan Italy, Chengdu China and Tokyo Japan.

For further information on EuroPCR, PCR London Valves, PCR Peripheral, PCR-CIT China Chengdu Valves, GulfPCR-GIM, AsiaPCR, AfricaPCR, PCR Tokyo Valves, and all PCR activities, please contact: Célia Vilà:

For more information, please visit: and follow us on Twitter using the hashtag #EuroPCR


Related Coronary Artery Disease Articles:

Human genes for coronary artery disease make them more prolific parents
Coronary artery disease may have persisted in human populations because the genes that cause this late-striking disease also contribute to greater numbers of children, reports Dr Sean Byars of The University of Melbourne and Associate Professor Michael Inouye of the Baker Heart and Diabetes Institute, Australia, in a study published June 22, 2017 in PLOS Genetics.
Ancient Egyptians to modern humans: Coronary artery disease genes benefit reproduction
Researchers have found that genes for coronary heart disease (CAD) also influence reproduction, so in order to reproduce successfully, the genes for heart disease will also be inherited.
Decreasing cocaine use leads to regression of coronary artery disease
People who use cocaine regularly are at high risk of coronary artery disease.
Association between sugary diet and coronary artery disease
What connection is there between food and drink with added sugar and coronary artery disease?
Coronary artery disease tests prompt patients toward healthier habits
Undergoing a computer tomographic angiography was a better motivator to get people with suspected coronary artery disease to adopt healthier lifestyle practices than an exercise electrocardiography and stress test.
Depressed patients have more frequent chest pain even in the absence of coronary artery disease
Depressed patients have more frequent chest pain even in the absence of coronary artery disease, according to results from the Emory Cardiovascular Biobank presented at ESC Congress today by Dr Salim Hayek, a cardiologist at Emory University School of Medicine in Atlanta, Georgia, US.1 The findings suggest that pain and depression may share a common neurochemical pathway.
Heart attack patients without obstructive coronary artery disease at high risk of residual angina
Patients without obstructive coronary artery disease (CAD) are just as at risk of angina as those with obstructive CAD, according to new research published today in the European Heart Journal-Quality of Care and Clinical Outcomes.
Diagnostic imaging can rule out coronary artery disease in patients with atypical chest pain
Non-invasive diagnostic imaging can rule out coronary artery disease (CAD) in about 50 percent of women with atypical chest pain who are at relatively low risk for CAD, while exposing them to only a modest dose of radiation.
Non-alcoholic fatty liver disease shown to affect the development of coronary artery calcification
Data revealed today at The International Liver CongressTM 2015 show that non-alcoholic fatty liver disease plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification.
Computational fluid dynamics in coronary plaques predict coronary artery disease
A computational fluid dynamics simulation based on 3-D luminal reconstructions of the coronary artery tree can be used to analyze local flow fields and flow profiling resulting from changes in coronary artery geometry.

Related Coronary Artery Disease Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...